Jianqin Lu, BPharm, PhD, is an Assistant Professor and Director in Pharmaceutics and Pharmacokinetics Track at R. Ken Coit College of Pharmacy, The University of Arizona, Tucson, USA. Dr. Lu received his PhD in Pharmaceutics from the University of Pittsburgh and had postdoc trainings at University of Chicago and UCLA David Geffen School of Medicine/California NanoSystems Institute. Dr. Lu joined UArizona in 2019 and his lab strives to develop innovative, safe, and efficacious therapeutics at the interface of drug delivery, synthetic chemistry, pharmaceutics, nanotechnology, biomaterials, and tumor immunology to address the pressing unmet needs in cancer and other diseases therapy and prevention.
Dr. Lu’s research work has been published in Nature Nanotechnology, Nature Communications, Biomaterials, etc, and has resulted in a Maximizing Investigators’ Research Award (MIRA) (R35) from NIH/NIGMS, a Pharmaceutical Research and Manufacturers of America (PhRMA) Foundation Research Starter Grant in Drug Delivery, and several pilot and seed grants from the State of Arizona’s Technology and Research Initiative Fund (TRIF)/BIO5 Institute and NIH-sponsored The Southwest Environmental Health Sciences Center.
Recipient of the Norman R. and Priscilla A. Farnsworth Award at the University of Pittsburgh, the NIH/NCI Ruth L. Kirschstein Institutional National Research Service Award (T32) in Tumor Immunology at UCLA, and the 2022 American Association of Colleges of Pharmacy (AACP) Pharmaceutics Research Award, Dr. Lu was the Secretary of Knowledge Management in AACP Pharmaceutics Section and serves as the Associate Editor for Frontiers in Medical Technology: Nano-Based Drug Delivery.You can follow Jianqin Lu on Twitter @JianqinLu_Lab or on LinkedIn
Read Jianqin’s Emerging Investigator article, ‘Surface-Modified Nanotherapeutics Targeting Atherosclerosis Efficiency’
Check out our interview with Jianqin below:
1. How do you feel about Biomaterials Science as a place to publish research on this topic?
Biomaterials Science is one of the leading journals in the field for biomaterials, drug delivery, and nanomedicine. I found Biomaterials Science is the perfect place to publish this piece of work, which enables widespread visibility to a large amount of audience.
2. What aspect of your work are you most excited about at the moment and what do you find most challenging about your research?
To create innovative, safe and efficacious nanotherapeutic platform for the improved drug and gene delivery for treating various diseases including cancers and atherosclerosis. To find clinically relevant animal models for testing the developed nanomedicines, which enables good correlation with human patients.
3. In your opinion, what are the most important questions to be asked/answered in this field of research?
How can the improved nanocarriers be used to further enhance the therapeutic delivery of various drugs.
